Investors & Media

Multiple opportunities for immuno-oncology

Investors Home

Developing non-viral gene transfer-based cell therapies to effectively access and treat the millions of people diagnosed globally each year with solid tumors by weaponizing the body’s immune system. Leveraging its multi-platform approach, Ziopharm is at the forefront of immuno-oncology.